BIRC5 and cancer: The advantage of using H/K-HELP-DCVAC is that antigen-pulsed activated DCs readily migrate to the TDLN and CD4+ and CD8+ T cells respond to DCs presenting WT-1 and survivin, which are expressed in most cancers, resulting in effective cancer therapy.